home / stock / ibio / ibio quote
Last: | $1.88 |
---|---|
Change Percent: | -4.57% |
Open: | $2.03 |
Close: | $1.97 |
High: | $2.03 |
Low: | $1.85 |
Volume: | 60,360 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.88 | $2.03 | $1.97 | $2.03 | $1.85 | 60,360 | 07-05-2024 |
$1.97 | $1.9 | $1.97 | $2.03 | $1.9 | 66,458 | 07-04-2024 |
$1.97 | $1.9 | $1.97 | $2.03 | $1.9 | 66,458 | 07-03-2024 |
$1.95 | $2.03 | $1.95 | $2.03 | $1.86 | 99,367 | 07-02-2024 |
$2.01 | $2.11 | $2.01 | $2.2193 | $2.01 | 71,699 | 07-01-2024 |
$2.11 | $2.1 | $2.11 | $2.1484 | $2.05 | 70,466 | 06-28-2024 |
$2.1 | $2.07 | $2.1 | $2.1 | $2.05 | 55,301 | 06-27-2024 |
$2.07 | $2.15 | $2.07 | $2.28 | $2.05 | 125,199 | 06-26-2024 |
$2.09 | $2.09 | $2.09 | $2.16 | $2.05 | 40,719 | 06-25-2024 |
$2.09 | $2.15 | $2.09 | $2.2 | $2.035 | 64,044 | 06-24-2024 |
$2.1 | $2.12 | $2.1 | $2.205 | $2.0301 | 164,090 | 06-21-2024 |
$2.14 | $2.32 | $2.14 | $2.334 | $2.11 | 124,403 | 06-20-2024 |
$2.28 | $2.37 | $2.28 | $2.39 | $2.28 | 60,514 | 06-19-2024 |
$2.28 | $2.37 | $2.28 | $2.39 | $2.28 | 60,514 | 06-18-2024 |
$2.3 | $2.5 | $2.3 | $2.5 | $2.26 | 127,171 | 06-17-2024 |
$2.56 | $2.56 | $2.56 | $2.57 | $2.51 | 58,378 | 06-14-2024 |
$2.57 | $2.53 | $2.57 | $2.5899 | $2.5 | 174,044 | 06-13-2024 |
$2.55 | $2.5 | $2.55 | $2.68 | $2.48 | 217,881 | 06-12-2024 |
$2.465 | $2.4 | $2.465 | $2.51 | $2.3513 | 135,362 | 06-11-2024 |
$2.4 | $2.36 | $2.4 | $2.4 | $2.2701 | 49,797 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio’s transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or th...
2024-05-28 07:30:05 ET Chardan Capital analyst issues BUY recommendation for IBIO on May 28, 2024 05:34AM ET. IBIO was trading at $2.19 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst recommendations are : 1 - Hold recommenda...
Strengthened cash position with investment by healthcare specialist investors Expanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company...